When evaluating a patient with potential myocarditis secondary to an Immune Checkpoint Inhibitor, what criteria should be used to aid in the diagnosis and treatment?
Bonaca’s criteria.
Bonaca MP et al. Myocarditis in the Setting of Cancer Therapeutics. Circulation 2019; 140(2):80-91. https://doi.org/10.1161/CIRCULATIONAHA.118.034497
Posted in Question Of The Day